Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Payables (2018 - 2025)

Historic Payables for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $3.0 billion.

  • Takeda Pharmaceutical's Payables rose 36.04% to $3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.0 billion, marking a year-over-year increase of 36.04%. This contributed to the annual value of $3.1 billion for FY2025, which is 1777.19% down from last year.
  • Takeda Pharmaceutical's Payables amounted to $3.0 billion in Q4 2025, which was up 36.04% from $3.0 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's Payables' 5-year high stood at $4.9 billion during Q1 2023, with a 5-year trough of $2.7 billion in Q4 2022.
  • In the last 5 years, Takeda Pharmaceutical's Payables had a median value of $3.0 billion in 2021 and averaged $3.2 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Payables soared by 3676.42% in 2022 and then crashed by 2472.63% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Payables (Quarter) stood at $3.1 billion in 2021, then fell by 12.68% to $2.7 billion in 2022, then rose by 21.3% to $3.3 billion in 2023, then decreased by 7.49% to $3.0 billion in 2024, then grew by 0.36% to $3.0 billion in 2025.
  • Its last three reported values are $3.0 billion in Q4 2025, $3.0 billion for Q3 2025, and $2.9 billion during Q2 2025.